TCGA-A8-A081-01A-11R-A00Z-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.460
- G2M_CHECKPOINT+0.440
- OXIDATIVE_PHOSPHORYLATION+0.380
- PROTEIN_SECRETION+0.380
- PI3K_AKT_MTOR_SIGNALING+0.270
- MITOTIC_SPINDLE+0.250
- DNA_REPAIR+0.210
- MTORC1_SIGNALING+0.200
- SPERMATOGENESIS+0.200
- INTERFERON_ALPHA_RESPONSE+0.180
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.670
- TNFA_SIGNALING_VIA_NFKB-0.470
- WNT_BETA_CATENIN_SIGNALING-0.450
- ANGIOGENESIS-0.420
- HEDGEHOG_SIGNALING-0.380
- COAGULATION-0.360
- UV_RESPONSE_DN-0.360
- P53_PATHWAY-0.320
- CHOLESTEROL_HOMEOSTASIS-0.310
- MYOGENESIS-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR11296797 | — | — | 0.877 |
| 2 | d01f4531-b145-414b-bc1c-0f1a148b771e | — | — | 0.853 |
| 3 | SRR12202422 | — | — | 0.853 |
| 4 | GSM6454730 | — | D | 0.852 |
| 5 | SRR5903554 | — | cohortA1 | 0.844 |
| 6 | TCGA-XF-AAML-01A-11R-A42T-07 | — | — | 0.844 |
| 7 | TCGA-18-3419-01A-01R-0980-07 | — | cohortSQ1 | 0.842 |
| 8 | R135 | — | — | 0.839 |
| 9 | SRR11296733 | — | — | 0.836 |
| 10 | SRR26320066 | — | — | 0.832 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.460 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.270 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.180 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.180 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.170 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| PEROXISOME | 0.050 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.040 | Inavolisib | — uncovered |